Ciprofloxacin and moxifloxacin each in a concentration of 30 mg/L, were mixed thoroughly with phosphate buffer (pH 7.2) containing one of the following suspensions of charcoal: 0.07%; 0.15%; 0.3%; 0.75%; 1.5%; and 3%. 
Introduction
Legionellae are ubiquitous in the environment and also cause community-and hospital-acquired respiratory tract infections (RTIs), of which pneumonia is the most important clinical presentation. Although erythromycin is considered the drug of choice as therapy of patients with legionella infections, the fluoroquinolones (particularly ciprofloxacin) have attracted interest as comparable, if not superior, alternatives because of their potent antimicrobial activities, favourable pharmacokinetic profiles, intracellular accumulation, low incidence of serious side-effects and absence of interactions with immunosuppressive agents such as cyclosporin A. This impression is based on the many successfully treated cases that have been recorded during the past 12 years, but no prospective, randomized clinical trials have confirmed the superiority of either the macrolides or the fluoroquinolones. 1 Owing to the drawbacks associated with treatment with erythromycin, 1 including abdominal cramps, nausea and vomiting, the activities of relevant novel antimicrobials against Le g i o n e l l a spp. are routinely being evaluated.
M o x i floxacin is a new 8-methoxyquinolone with enhanced in-vitro activity against Gram-positive bacteria and anaerobes, compared with currently available quinolones, whilst retaining marked activity against Gram-negative bacteria. 2 The aim of the present study was to determine the in-vitro activities of moxifloxacin, ciprofloxacin, erythromycin and rifampicin against a variety of Legionella pneumophila and non-pneumophila isolates and to investigate the effects of the medium on the results of susceptibility testing.
Materials and methods

Bacterial strains
The following 52 strains, which represented both clinical isolates from Germany and reference strains, were studied: L. pneumophila serogroup 1 (n ϭ 21); L. pneumophila serogroups 2-14 (n ϭ 18); Legionella micdadei (n ϭ 2); Legionella bozemanii serogroup 1 (n ϭ 2); L. bozemanii serogroup 2 (n ϭ 1); Legionella dumofii (n ϭ 1); Legionella gormanii (n ϭ 1); Legionella jordanis (n ϭ 1); Legionella longbeachae serogroups 1 (n ϭ 1) and 2 (n ϭ 1); Legionella feelei serogroups 1 (n ϭ 1) and 2 (n ϭ 1); and Legionella hackeliae (n ϭ 1). Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 259922 were included as controls.
Antibiotics
The following antibiotics were tested: moxifloxacin (Bayer AG, Leverkusen, Germany); ciprofloxacin (Bayer AG); erythromycin and rifampicin (Sigma Chemical Co., St Louis, MO, USA.
antibacterial solutions and charcoal suspensions were each 5 mL. The mixtures were incubated at room temperature and aliquots (0.1 mL) were withdrawn after 5, 20, 40 and 60 min and centrifuged at 15,000g. The concentration of the antibiotics in the supernatants were determined by a standard cup plate agar diffusion method. A spore suspension of Bacillus subtilis No. 2 (Difco Laboratories, Augsburg, Germany) was used as the indicator organism and the medium was Iso-Sensitest agar (Difco Laboratories). The plates were incubated at 37°C for 18 h, after which the zones of inhibition were measured.
Quinolone diffusion through agar
The times required for ciprofloxacin and moxifloxacin to diffuse through agar (3.4 depths of 5.1 or 6.8 mm were determined by a method described previously. 3 Known concentrations (30, 15, 3.75, 0.94 and 0.23 mg/L) of each quinolone were dissolved in 10 mL of agar which was poured into 8.5-mm diameter plates, giving a depth of 1.7 mm. This was overlaid with 10, 20 or 30 mL of quinolone-free agar, which was either charcoal-free or contained 0.15% charcoal. Plates were incubated for 4 h at 37°C to assess diffusion of quinolone through the agar. The drug concentrations at the upper surfaces of the agar were determined by applying drug-free paper discs (No. 2668; Schleicher and Schüll, Dassel, Germany) to the surface and allowing liquid to be absorbed. After 15 s, the discs were removed, thereby allowing standard volumes of liquid to be obtained. Drug concentrations were measured by placing the discs on agar seeded with a spore suspension of the indicator organism, B. subtilis. Standards were prepared by placing Schleicher & Schüll filter paper discs (No. 2668) for 15 s on to the surfaces of agar of the same depths as those of the media containing the quinolones, transferring the discs to assay plates and, following incubation and measurement of inhibition zones, devising reference regression lines.
MIC determinations
MICs were determined by an agar dilution method; the test medium was buffered charcoal yeast extract agar containing 0.015% ␣-ketoglutarate (BCYE␣) and 5% charcoal. Inocula of c. 10 3 cfu and c.10 5 cfu of each strain were spotted on to the plates with a multi-point inoculator (Denley, Billinghurst, UK) and the plates were incubated at 35°C for 2 days in an atmosphere containing 5% CO 2 .
Results
Binding of quinolones to charcoal
Both ciprofloxacin and moxifloxacin were markedly bound by charcoal; at concentrations of 0.3-3%, no antibacterial activity was detected after у5 min. At the lower charcoal concentrations tested, the extent and speed of binding were less and varied with the concentration (Figure 1) . At a concentration of 0.15%, almost total binding of moxifloxacin (92.2%) and ciprofloxacin (92.9%) was observed at 60 min, while at 0.07%, approximately 79% of each quinolone was bound after 40 min. A charcoal concentration of 0.15% produced 93.5% and 90.5% binding of erythromycin and rifampicin respectively (data not shown).
Quinolone diffusion through agar
Diffusion of moxifloxacin and ciprofloxacin from the lower layer of the agar to the surface of the overlying layer was rapid, uniform distribution of the drugs being throughout the 3.4 mm agar layer after Ͻ 2 h. Diffusion from the lower layers into the upper layers of the agar that were 5.1 mm and 6.8 mm deep was less rapid (Figure 2 ), but the diffusion time was independent of the concentration of the quinolone in the lower layer. The presence of charcoal in the upper layer resulted in a marked reduction in the drug concentration at the surface, compared with the charcoalfree plates. the concentrations of the quinolones at the agar surfaces were 9.1% lower (data not shown).
In-vitro activities
The geometric mean MICs of moxifloxacin and ciprofloxacin for the Legionella spp. isolates, as determined with both high and low inocula, were the same (Table) ; the values at the lower inoculum were four-fold lower than those at the higher inoculum. The geometric mean MICs of erythromycin were three-to four-fold higher than those of the quinolones, while the geometric mean MICs of rifampicin were three-to five-fold lower. The geometric mean MICs were corrected to take account of the bound fraction of each drug, only the unbound fraction having antibacterial activity. 4 The diffusion of moxifloxacin through alginate was similar to its penetration through agar (data not shown). Free fractions of the antimicrobial agents were: moxifloxacin 7.8%; ciprofloxacin 7.1%; erythromycin 6.5%; and rifampicin 9.5%. The geometric mean MICs as determined on BCYE␣ were set as 100% and corrected for the free percentage of each antibacterial agent studied.
Discussion
Several fluoroquinolones, including ciprofloxacin, have been shown to have potent activities against legionellae. [5] [6] [7] [8] [9] [10] [11] [12] [13] However, the MICs of individual drugs have varied from study to study and this has been attributed to differences in the composition of the media used for susceptibility testing; in particular, charcoal has been reported to adversely affect the in-vitro activities of quinolones. [14] [15] [16] [17] As the medium commonly used for the isolation of Legionella spp. from clinical specimens is BCYE agar to which is added charcoal as a scavenger of toxic substances, we also used BCYE␣ agar for susceptibility testing in the present study. Other media support the growth of legionellae poorly. 18 However, because antibacterials are known to bind to charcoal, the effects of this substance on the in-vitro activities of two quinolones and comparator anti-legionella drugs were investigated. Ciprofloxacin and moxifloxacin were rapidly and almost completely bound to charcoal, irrespective of whether liquid or solid medium was used, the unbound fraction being approximately 8% of the total amount of drug. Erythromycin and rifampicin were similarly almost completely bound to the charcoal. Thus, it is expected that the MICs of antibiotics for Le g i o n e l l a spp. will be markedly higher when the susceptibility test medium contains charcoal. Diffusion of moxifloxacin through agar of different depths is almost directly related to the depth: diffusion through a 5 mm layer was rapid and complete within 4 h. This may suggest that moxifloxacin penetrates rapidly and effectively into extracellular matrices, protecting bacteria from host defences.
The MIC 90 of ciprofloxacin and moxifloxacin were in accord with those reported by other investigators who also used charcoal-containing media. 5 However, as only the unbound fraction of an antibiotic has antibacterial activity, the MICs determined in such media should be corrected for quinolone binding to charcoal. In this study, correction of the MICs resulted in a Ͼ10-fold reduction in the original values. These mathematically derived data compare favourably with those obtained with charcoal-free media, although these media may not support optimal growth. 19 Hoogkamp-Korstanje 20 compared the in-vitro activities of ciprofloxacin, ofloxacin and levofloxacin (MIC 90 s, 0.03 mg/L) with those of sparfloxacin and trovafloxacin (MIC 90 s Ͻ 0.015 mg/L) for L. pneumophila isolates with charcoalfree buffered starch yeast extract. These results fall within the same range as the corrected geometric means MICs reported here, thereby validating our results. These data and those reported by other confirm that all of the novel quinolones possess potent in-vitro activities against Legionella spp. However, in-vitro activities do not invariably correlate with clinical response, particularly in the case of Legionella spp. which are predominantly intracellular pathogens. Only drugs that are able to penetrate into phagocytes and that are active therein can be used effectively as treatment of patients with legionellosis. 21 Even total intracellular drug concentrations do not necessarily correlate strongly with intracellular activity. For example, macrolides which are almost equally distributed between the cell soluble fraction and lysosomes are markedly less active against L. pneumophila than ciprofloxacin, which is not associated with sub-cellular organelles. Although intracellular concentrations of antibiotics such as erythromycin and azithromycin exceed those of ciprofloxacin by between five-and nine-fold, ciprofloxacin exhibited 1.5-to 2.7-fold greater intracellular activity against L. pneumophila. 22 As moxifloxacin has also been shown to accumulate intracellularly, 23 its activity against Legionella spp. should be confirmed with cell cultures, in animal models and, ultimately, in clinical trials.
